

**Alembic Pharmaceuticals Limited**

**Familiarization Programmes for Independent Directors**

Name of the Independent Director	No. of programmes attended by the Independent Directors			No. of hours spent by the Independent Directors in such programmes		
	During the year (2021-22)	Cumulative till date (2014-15 Onwards)	Other relevant details	During the year (2021-22)	Cumulative till date (2014-15 Onwards)	Other relevant details
Mr. K. G. Ramanathan	1	15	-	0:55	18:05	-
Mr. Pranav Parikh	1	14	-	0:55	15:55	-
Mr. Paresh Saraiya	1	16	-	0:55	19:10	-
Dr. Archana Hingorani	1	16	-	0:55	18:25	-

**Details of Familiarization Programmes imparted to Independent Directors:**

Date of the Programmes	Details of the Programmes
4 <sup>th</sup> February, 2015	(a) The Roles, Rights, Responsibilities and Duties of Independent Directors. (b) The Company, Nature of Industry in the Company operates, business model of the Company.
31 <sup>st</sup> July, 2015	Research & Development Activities of the Company.
27 <sup>th</sup> October, 2015	Human Resources Activities of the Company.
21 <sup>st</sup> January, 2016	(a) US Operations (b) Strategy and Business Potential (c) Overview of Capex Plans
25 <sup>th</sup> January, 2017	Overview on on-going capital projects of the Company.
3 <sup>rd</sup> May, 2017	(a) CSR Activities carried out in F.Y. 2016-17 and proposed for F.Y. 2017-18. (b) Preparedness on GST.
20 <sup>th</sup> July, 2017	Proposed Growth Strategy, Capital Investments particularly in R & D and working of Joint Ventures (JVs).



**ALEMBIC PHARMACEUTICALS LIMITED**

7 <sup>th</sup> November, 2017	(a) US Business. (b) EU/ROW/Algeria. (c) Competitive Scenario and our strategy. (d) Orit Acquisition. (e) Organogram & HR Practices. (f) Projects. (g) Timelines and tentative Mid Term Plan.
31 <sup>st</sup> January, 2018	(a) R & D and Market Trends. (b) Human Resources. (c) APL Consolidated Budget and IBU Budget. (d) Operations and Projects.
16 <sup>th</sup> May, 2018	IBU Business.
26 <sup>th</sup> July, 2018	(a) CSR Activities. (b) New process for all statutory compliances. (c) Recent amendments in Companies Act, 2013 & SEBI Regulations.
22 <sup>nd</sup> October, 2018	(a) Competitive scenario, strategy, capital expenditure and R & D for International Business. (b) Branded Business.
22 <sup>nd</sup> January, 2019	(a) IBU Budget. (b) Operations & Projects.
8 <sup>th</sup> May, 2019	Projects.
24 <sup>th</sup> October, 2019	Business Overview.
23 <sup>rd</sup> April, 2020	(a) Business Overview. (b) Covid-19 Precautions and Preparedness.
29 <sup>th</sup> June, 2021	(a) EHS practices & compliance status. (b) Legal Compliance Management System.



**ALEMBIC PHARMACEUTICALS LIMITED**